+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Biological Therapy Market by Therapy Type, Application, Administration Route, End User, Distribution Channel - Global Forecast to 2030- Product Image
Cancer Biological Therapy Market by Therapy Type, Application, Administration Route, End User, Distribution Channel - Global Forecast to 2030- Product Image
Sale

Cancer Biological Therapy Market by Therapy Type, Application, Administration Route, End User, Distribution Channel - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011650
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Cancer Biological Therapy Market grew from USD 72.42 billion in 2024 to USD 81.25 billion in 2025. It is expected to continue growing at a CAGR of 11.63%, reaching USD 140.21 billion by 2030.

Setting the Stage for Cancer Biological Therapy Innovation

Cancer remains a pervasive global health challenge, with traditional treatment modalities often constrained by toxicity profiles and limited efficacy in advanced disease stages.

In recent years, biological therapies have emerged as a revolutionary approach, harnessing the body’s immune system and molecular tools to deliver precision interventions that transcend the boundaries of conventional chemotherapy and radiotherapy.

This executive summary distills comprehensive research into the current state of cancer biological therapy, highlighting pivotal developments, market dynamics, and strategic recommendations for stakeholders across the value chain.

As decision-makers navigate an increasingly complex environment-shaped by evolving regulations, tariff reforms, and shifting patient expectations-they require a clear, data-driven framework to guide investment, innovation, and market entry strategies.

Fundamental Shifts Redefining Cancer Biological Treatment

The landscape of cancer biological treatment is undergoing a profound transformation driven by breakthroughs in cellular engineering and molecular targeting techniques.

Personalized medicine at the molecular level has redefined the concept of targeted therapy by leveraging genomic profiling and biomarker-driven strategies to match interventions with individual tumor signatures.

Regulatory agencies have embraced adaptive approval frameworks and accelerated pathways, enabling promising therapies to reach patients more swiftly while maintaining rigorous safety standards.

Advancements in digital health and data analytics are streamlining clinical trial design and patient monitoring across complex immuno-oncology studies, reducing time to market and optimizing resource allocation.

Consequently, the convergence of these developments is fostering a dynamic market environment defined by strategic partnerships, cross-sector innovation, and a renewed focus on patient-centric solutions.

Impact of United States Tariffs on Cancer Biologics in 2025

In 2025, cumulative adjustments to United States import tariffs on biologic reagents and therapeutic agents will reshape cost structures across the value chain.

Rising duties on key raw materials and contract manufacturing services are driving an uptick in production expenses at overseas sites and pressuring margins for established players.

In response, leading manufacturers are accelerating investments in domestic capacity to mitigate risk, enhance supply chain resilience, and maintain pricing discipline for payers and providers.

As a result, market participants must recalibrate sourcing strategies, engage proactively with regulators to address trade policy volatility, and explore innovation in process intensification to offset tariff-related headwinds.

Segmenting the Cancer Biological Therapy Market for Strategic Clarity

Therapy type segmentation reveals a diverse portfolio of modalities addressing the complex immunologic mechanisms of cancer, with cancer vaccines reinvigorating adaptive immune responses and CAR T-cell therapy delivering gene-engineered lymphocytes that target tumor antigens with precision.

Cytokine therapeutics harness signaling molecules to modulate immune cell behavior, while gene therapy applications enable direct correction or modification of oncogenic pathways. Oncolytic viral therapies exploit engineered viruses to selectively infect and lyse malignant cells, broadening the arsenal of interventions against resistant tumor phenotypes.

Within the established realm of monoclonal antibodies, chimeric constructs continue to deliver clinically validated efficacy, even as fully human and humanized formats gain traction for their reduced immunogenicity and improved safety profiles. Murine subtypes maintain niche applications where proven antigen specificity drives clinical preference.

Application segmentation underscores disease-specific demand patterns, with breast and colorectal cancers commanding significant research funding and commercial focus. Hematologic malignancies benefit from the rapid adoption of cell therapies, while melanoma and non-small cell lung cancer remain key areas for next-generation biologics. Prostate cancer therapy continues to evolve through combination regimens incorporating immunomodulatory agents.

Delivery modalities extend beyond intravenous infusions to subcutaneous and intramuscular regimens that prioritize patient convenience, while emerging oral platforms leverage advanced formulation techniques. End users range from ambulatory care centers and hospital settings to home healthcare and research laboratories with evolving infrastructure for complex therapies. Distribution strategies blend direct sales approaches with hospital, online, and retail pharmacy partnerships to ensure broad market coverage.

Regional Dynamics Shaping Global Cancer Biological Therapies

The Americas region offers a robust ecosystem for cancer biological therapies, underpinned by well-established regulatory frameworks and deep capital markets. The United States remains a global leader in clinical trial activity and commercialization pathways, while Canada continues to incentivize innovation through collaborative research initiatives and public funding models.

In Europe, Middle East and Africa, regulatory heterogeneity shapes adoption timelines. Western European nations benefit from centralized approval mechanisms and extensive reimbursement programs, whereas emerging economies in the Middle East and Africa present both challenges in infrastructure and growing opportunities as healthcare systems modernize.

Asia-Pacific stands out as the fastest-growing market segment, driven by large patient populations in China and India, increasing governmental support for biotechnology ventures, and a surge in localized manufacturing capacity. Japan and Australia maintain strong research pipelines and regulatory agility that facilitate rapid product launches.

The interplay between these regions underscores the necessity for tailored market entry strategies that account for local regulatory landscapes, pricing dynamics, and healthcare infrastructure, ensuring that innovators can capitalize on both mature and emerging opportunities.

Leading Players Driving Innovation and Market Momentum

The competitive landscape in cancer biological therapy is dominated by organizations that combine deep research capabilities with strategic alliance networks. Leading innovators are differentiating through advanced clinical pipelines in cell and gene therapies, while pursuing strategic acquisitions to bolster their immuno-oncology portfolios.

Novartis has established a benchmark in CAR T-cell treatments, translating cutting-edge science into commercial success and expanding global manufacturing nodes to meet rising demand. Amgen’s foray into bispecific antibody platforms reflects its focus on modular biologic design, and Roche continues to leverage its oncology heritage through partnership-driven expansions across multiple therapeutic targets.

Gilead’s strategic acquisitions in cell therapy and Merck’s immuno-oncology collaborations underscore the importance of M&A and joint ventures for rapid capability enhancement. Pfizer and Bristol-Myers Squibb are consolidating their market positions through co-development agreements and co-promotion strategies that optimize resource allocation and accelerate time to market.

Across the board, companies are investing in next-generation manufacturing technologies, including single-use bioreactors and process intensification, to improve scalability and cost efficiency, positioning themselves competitively for the evolving commercial landscape.

Actionable Strategies for Industry Leadership in Biologics

Industry leaders should prioritize the expansion of domestic manufacturing footprint to circumvent tariff pressures and bolster supply chain resilience, leveraging emerging technologies in continuous bioprocessing to drive operational efficiency.

Strategic diversification of research pipelines-incorporating both established monoclonal formats and novel modalities such as oncolytic viral and gene therapies-will mitigate clinical risk and enable entry into unmet medical needs across multiple cancer indications.

Early engagement with regulatory authorities through adaptive pathway programs and health technology assessment bodies can streamline approval processes and secure favorable reimbursement conditions, ensuring faster patient access and sustained revenue streams.

A collaborative approach that integrates digital health platforms, real-world evidence generation, and payor partnerships will enhance value demonstration. Simultaneously, targeted expansion into high-growth regions requires tailored market access strategies and investment in local stakeholder engagement.

Rigorous Research Approach Underpinning Market Insights

This analysis is grounded in a comprehensive research framework that integrates both primary and secondary methodologies to ensure robust market insights.

Primary research comprised in-depth interviews with key opinion leaders, senior executives, and technical experts across the biologics ecosystem, yielding qualitative perspectives on emerging trends, regulatory dynamics, and investment priorities.

Secondary research incorporated extensive review of peer-reviewed publications, clinical trial registries, regulatory filings, and proprietary databases, facilitating quantitative validation of market characteristics and competitive positioning.

Data triangulation and cross-validation techniques were applied to reconcile discrepancies and enhance the reliability of conclusions. Coverage spans major geographic regions and therapy segments defined by type, application, route, end user, and distribution channel, with rigorous data quality protocols maintained throughout.

The methodological rigor across all stages of data collection and analysis underpins the credibility of the strategic recommendations presented herein.

Concluding Perspectives on the Future of Cancer Biologics

The convergence of technological breakthroughs, evolving regulatory frameworks, and strategic industry collaborations is reshaping the cancer biological therapy landscape, offering unprecedented avenues for innovation and patient impact.

Key market drivers, including tariff-induced supply chain realignment and segmentation-based growth strategies, underscore the importance of agility and market-specific insights for stakeholders seeking to navigate this dynamic environment.

Regional nuances-from mature markets in the Americas to high-potential growth in Asia-Pacific-necessitate customized approaches to market entry, commercialization, and stakeholder engagement that align with local healthcare ecosystems.

By synthesizing these perspectives, decision-makers can chart a course toward sustainable value creation, balancing scientific ambition with operational pragmatism to unlock the next generation of cancer biologics.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Therapy Type
    • Cancer Vaccines
    • CAR T-Cell Therapy
    • Cytokine Therapy
    • Gene Therapy
    • Monoclonal Antibodies
      • Chimeric
      • Human
      • Humanized
      • Murine
    • Oncolytic Viral Therapy
  • Application
    • Breast Cancer
    • Colorectal Cancer
    • Hematologic Malignancies
    • Melanoma
    • Non-Small Cell Lung Cancer
    • Prostate Cancer
  • Administration Route
    • Intramuscular
    • Intravenous
    • Oral
    • Subcutaneous
  • End User
    • Ambulatory Care Centers
    • Home Healthcare
    • Hospitals
    • Research Laboratories
    • Specialty Clinics
  • Distribution Channel
    • Direct Sales
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc
  • Bristol-Myers Squibb Company
  • Novartis International AG
  • Amgen Inc
  • Pfizer Inc
  • Johnson & Johnson
  • AstraZeneca plc
  • Gilead Sciences, Inc
  • AbbVie Inc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Biological Therapy Market, by Therapy Type
8.1. Introduction
8.2. Cancer Vaccines
8.3. CAR T-Cell Therapy
8.4. Cytokine Therapy
8.5. Gene Therapy
8.6. Monoclonal Antibodies
8.6.1. Chimeric
8.6.2. Human
8.6.3. Humanized
8.6.4. Murine
8.7. Oncolytic Viral Therapy
9. Cancer Biological Therapy Market, by Application
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Hematologic Malignancies
9.5. Melanoma
9.6. Non-Small Cell Lung Cancer
9.7. Prostate Cancer
10. Cancer Biological Therapy Market, by Administration Route
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Oral
10.5. Subcutaneous
11. Cancer Biological Therapy Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Home Healthcare
11.4. Hospitals
11.5. Research Laboratories
11.6. Specialty Clinics
12. Cancer Biological Therapy Market, by Distribution Channel
12.1. Introduction
12.2. Direct Sales
12.3. Hospital Pharmacies
12.4. Online Pharmacies
12.5. Retail Pharmacies
13. Americas Cancer Biological Therapy Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cancer Biological Therapy Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cancer Biological Therapy Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. Merck & Co. Inc
16.3.3. Bristol-Myers Squibb Company
16.3.4. Novartis International AG
16.3.5. Amgen Inc
16.3.6. Pfizer Inc
16.3.7. Johnson & Johnson
16.3.8. AstraZeneca plc
16.3.9. Gilead Sciences, Inc
16.3.10. AbbVie Inc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CANCER BIOLOGICAL THERAPY MARKET MULTI-CURRENCY
FIGURE 2. CANCER BIOLOGICAL THERAPY MARKET MULTI-LANGUAGE
FIGURE 3. CANCER BIOLOGICAL THERAPY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CANCER BIOLOGICAL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 55. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 56. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 57. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 59. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 62. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 63. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 65. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 71. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 93. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 94. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 96. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 98. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 99. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 100. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 102. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 111. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 112. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 114. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 116. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 117. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 118. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 119. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 120. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 123. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 124. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 130. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 132. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 134. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 135. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 136. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 138. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 140. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 141. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 142. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 143. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 144. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 147. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 148. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 150. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 153. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 154. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 156. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 159. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 160. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 162. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. FINLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 165. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 166. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 168. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 176. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 177. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 178. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 179. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 180. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. EGYPT CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 183. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 184. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 186. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. TURKEY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 192. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. ISRAEL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 195. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 196. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 198. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. NORWAY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 200. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 201. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 202. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 204. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. POLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 206. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 207. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 208. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 210. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. SWITZERLAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 219. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 220. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 221. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 222. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 223. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. CHINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 226. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 227. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 229. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. INDIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 231. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 232. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 233. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 234. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 235. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. JAPAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 246. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 247. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. SOUTH KOREA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 249. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 250. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 251. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 253. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. INDONESIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 256. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 257. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 258. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 259. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 260. THAILAND CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 261. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 262. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 263. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 264. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 265. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. PHILIPPINES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 269. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 270. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 271. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. MALAYSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 274. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 275. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 276. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 277. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 278. SINGAPORE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 280. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 281. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 282. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 283. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 284. VIETNAM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 285. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 286. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD MILLION)
TABLE 287. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 288. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 289. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. TAIWAN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
TABLE 292. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

Companies Mentioned

The companies profiled in this Cancer Biological Therapy market report include:
  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc
  • Bristol-Myers Squibb Company
  • Novartis International AG
  • Amgen Inc
  • Pfizer Inc
  • Johnson & Johnson
  • AstraZeneca plc
  • Gilead Sciences, Inc
  • AbbVie Inc

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 81.25 Billion
Forecasted Market Value ( USD ) by 2030 $ 140.21 Billion
Compound Annual Growth Rate11.6%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Cancer Biological Therapy - Global Strategic Business Report - Product Image

Cancer Biological Therapy - Global Strategic Business Report

  • Report
  • 211 Pages
  • Global
From
Targeted Therapy Drugs for Melanoma Market by Mechanism Of Action, Route Of Administration, Treatment Line, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Targeted Therapy Drugs for Melanoma Market by Mechanism Of Action, Route Of Administration, Treatment Line, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 181 Pages
  • Global
From
Cancer Biological Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Cancer Biological Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
NDDS in Cancer Therapy Market by Product Type, Drug Type, Application, Technology Platform - Global Forecast to 2030 - Product Image

NDDS in Cancer Therapy Market by Product Type, Drug Type, Application, Technology Platform - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Antineoplastic Agents - Global Strategic Business Report - Product Image

Antineoplastic Agents - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.